Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system… Read More
Play Podcast How this geneticist went from struggling student to startup founder to selling her company for $102M Play More than 20 years ago, Claudia Mitchell arrived in Paris to pursue a doctorate degree in molecular biology — with a… Read More
Cell therapies are giving Seattle an edge in biotech, driving three acquisitions in under a month On a chilly Monday morning in January, Seattle awoke to the news that one of its most promising companies, Juno… Read More
